GLP-1 Makers Face Surge in Vision Loss Lawsuits as NAION Link Debated

Key points

• Plaintiffs claim GLP-1 receptor agonists cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to permanent blindness.
• Novo Nordisk and Eli Lilly dispute the claims, stating that current studies do not prove their drugs cause NAION and that the overall health benefits outweigh the risks.
• The European Medicines Agency has added NAION as a 'very rare' adverse reaction to semaglutide labels, but the U.S. FDA has not issued a similar warning.
• Research is mixed: some studies show a modest increase in risk for semaglutide users, while others find no association, with experts noting that diabetes itself is a major risk factor for NAION.

Background

This litigation follows earlier reports in August and September 2026 regarding growing legal challenges against GLP-1 medications. Previous coverage highlighted that while these drugs offer significant benefits for weight loss and cardiovascular health, concerns over side effects, including potential hair loss and vision issues, have prompted increased regulatory scrutiny and patient lawsuits.

How outlets are covering it

Fox News emphasizes the lack of treatment for NAION and quotes an ophthalmologist who believes the benefits of GLP-1 drugs generally outweigh the rare vision risks, unless a patient has specific anatomical risk factors. USA Today highlights the scale of the legal action, noting that thousands of lawsuits have been filed, including specific cases in New Jersey and Pennsylvania, and points out that while U.S. labels have not been updated, European and other international labels now include NAION warnings. Both sources agree that the evidence linking the drugs to the condition is observational and inconclusive, but they differ in emphasis: Fox focuses on the clinical debate, while USA Today focuses on the legal and regulatory discrepancies between the U.S. and other countries.

Why it matters

The outcome of these lawsuits and the ongoing regulatory review could influence how millions of patients and doctors weigh the benefits of GLP-1 medications against potential side effects. If a causal link is established, it could lead to label changes in the U.S. and impact the widespread use of these drugs for weight loss and diabetes management.

What to watch

The FDA is currently reviewing available evidence regarding a possible association between semaglutide and NAION. The consolidated lawsuits are expected to proceed through the courts, and the outcome may influence whether U.S. drug labels are updated to include NAION warnings, similar to those in Europe and other regions.